52 filings
8-K
INBX
Inhibrx Inc
9 May 24
Inhibrx Reports First Quarter 2024 Financial Results
4:08pm
8-K
INBX
Inhibrx Inc
8 May 24
Other Events
4:42pm
8-K
INBX
Inhibrx Inc
12 Mar 24
Other Events
4:02pm
8-K
INBX
Inhibrx Inc
28 Feb 24
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9:12am
8-K
INBX
Inhibrx Inc
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
v2r2 6cz1awic3w
9 Nov 23
Inhibrx Reports Third Quarter 2023 Financial Results
4:03pm
8-K
66b2sv9ocw o7i
2 Nov 23
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
9:16am
8-K
v4h uyo7x0
19 Sep 23
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
4:03pm
8-K
kzx9js3w1f1
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
8-K
6zeyrhgt
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
4cjf 7zkwr2qaiv75
30 May 23
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:03am
8-K
45a 67tw4
25 May 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
ys7lq2
8 May 23
Inhibrx Reports First Quarter 2023 Financial Results
4:05pm
8-K
2j2xulywwu
26 Apr 23
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
9:01am
8-K
odrd 9flfv9d8s0
10 Mar 23
Regulation FD Disclosure
7:02pm
8-K
j58cl 2knxxfhf3k2x
6 Mar 23
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
4:04pm
8-K
zhjh1mu
16 Nov 22
Regulation FD Disclosure
9:01am
8-K
v2qh5dt252b5jwr
7 Nov 22
Inhibrx Reports Third Quarter 2022 Financial Results
4:05pm
8-K
mbljun
26 Oct 22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:10pm
8-K
2dx3ai
4 Oct 22
Entry into a Material Definitive Agreement
8:02am